Biotechnology
Compare Stocks
2 / 10Stock Comparison
ICU vs TPVG
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
ICU vs TPVG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Asset Management |
| Market Cap | $29M | $226M |
| Revenue (TTM) | $881K | $97M |
| Net Income (TTM) | $-14M | $46M |
| Gross Margin | 95.3% | 83.5% |
| Operating Margin | -15.8% | 77.9% |
| Forward P/E | — | 6.5x |
| Total Debt | $574K | $469M |
| Cash & Equiv. | $2M | $20M |
ICU vs TPVG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| SeaStar Medical Hol… (ICU) | 100 | 1.9 | -98.1% |
| TriplePoint Venture… (TPVG) | 100 | 55.2 | -44.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ICU vs TPVG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ICU is the clearest fit if your priority is growth exposure.
- Rev growth 12.0%, EPS growth 78.1%
- 12.0% revenue growth vs TPVG's 36.6%
- +280.5% vs TPVG's +8.6%
TPVG carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 0.83, yield 18.4%
- 87.8% 10Y total return vs ICU's -98.1%
- Lower volatility, beta 0.83
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.0% revenue growth vs TPVG's 36.6% | |
| Quality / Margins | 50.6% margin vs ICU's -15.5% | |
| Stability / Safety | Beta 0.83 vs ICU's 1.06 | |
| Dividends | 18.4% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +280.5% vs TPVG's +8.6% | |
| Efficiency (ROA) | 5.6% ROA vs ICU's -88.0% |
ICU vs TPVG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
TPVG leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
TPVG is the larger business by revenue, generating $97M annually — 110.3x ICU's $881,000. TPVG is the more profitable business, keeping 50.6% of every revenue dollar as net income compared to ICU's -15.5%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $881,000 | $97M |
| EBITDAEarnings before interest/tax | -$14M | $63M |
| Net IncomeAfter-tax profit | -$14M | $46M |
| Free Cash FlowCash after capex | -$14M | $35M |
| Gross MarginGross profit ÷ Revenue | +95.3% | +83.5% |
| Operating MarginEBIT ÷ Revenue | -15.8% | +77.9% |
| Net MarginNet income ÷ Revenue | -15.5% | +50.6% |
| FCF MarginFCF ÷ Revenue | -16.1% | -58.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +169.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +88.2% | -100.0% |
Valuation Metrics
Evenly matched — ICU and TPVG each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $29M | $226M |
| Enterprise ValueMkt cap + debt − cash | $28M | $674M |
| Trailing P/EPrice ÷ TTM EPS | -0.73x | 4.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 6.50x |
| PEG RatioP/E ÷ EPS growth rate | — | 4.50x |
| EV / EBITDAEnterprise value multiple | — | 8.90x |
| Price / SalesMarket cap ÷ Revenue | 215.62x | 2.32x |
| Price / BookPrice ÷ Book value/share | — | 0.63x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
Evenly matched — ICU and TPVG each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
TPVG delivers a 13.1% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-119 for ICU. On the Piotroski fundamental quality scale (0–9), ICU scores 6/9 vs TPVG's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -119.2% | +13.1% |
| ROA (TTM)Return on assets | -88.0% | +5.6% |
| ROICReturn on invested capital | — | +7.2% |
| ROCEReturn on capital employed | — | +9.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | — | 1.33x |
| Net DebtTotal debt minus cash | -$1M | $449M |
| Cash & Equiv.Liquid assets | $2M | $20M |
| Total DebtShort + long-term debt | $574,000 | $469M |
| Interest CoverageEBIT ÷ Interest expense | -209.88x | 2.15x |
Total Returns (Dividends Reinvested)
TPVG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TPVG five years ago would be worth $8,097 today (with dividends reinvested), compared to $190 for ICU. Over the past 12 months, ICU leads with a +280.5% total return vs TPVG's +8.6%. The 3-year compound annual growth rate (CAGR) favors TPVG at -2.6% vs ICU's -53.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +85.1% | -12.7% |
| 1-Year ReturnPast 12 months | +280.5% | +8.6% |
| 3-Year ReturnCumulative with dividends | -90.1% | -7.5% |
| 5-Year ReturnCumulative with dividends | -98.1% | -19.0% |
| 10-Year ReturnCumulative with dividends | -98.1% | +87.8% |
| CAGR (3Y)Annualised 3-year return | -53.7% | -2.6% |
Risk & Volatility
Evenly matched — ICU and TPVG each lead in 1 of 2 comparable metrics.
Risk & Volatility
TPVG is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than ICU's 1.06 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICU currently trades 96.3% from its 52-week high vs TPVG's 74.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.06x | 0.83x |
| 52-Week HighHighest price in past year | $5.05 | $7.53 |
| 52-Week LowLowest price in past year | $0.22 | $4.48 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +74.0% |
| RSI (14)Momentum oscillator 0–100 | 59.8 | 55.8 |
| Avg Volume (50D)Average daily shares traded | 149K | 498K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
TPVG is the only dividend payer here at 18.40% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $8.95 |
| # AnalystsCovering analysts | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | +18.4% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $1.02 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
TPVG leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
ICU vs TPVG: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ICU or TPVG a better buy right now?
TriplePoint Venture Growth BDC Corp.
(TPVG) offers the better valuation at 4. 6x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate TriplePoint Venture Growth BDC Corp. (TPVG) a "Hold" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ICU or TPVG?
Over the past 5 years, TriplePoint Venture Growth BDC Corp.
(TPVG) delivered a total return of -19. 0%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: TPVG returned +93. 3% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ICU or TPVG?
By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.
(TPVG) is the lower-risk stock at 0. 83β versus SeaStar Medical Holding Corporation's 1. 06β — meaning ICU is approximately 27% more volatile than TPVG relative to the S&P 500.
04Which is growing faster — ICU or TPVG?
On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78.
1% year-over-year, compared to 48. 8% for TriplePoint Venture Growth BDC Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ICU or TPVG?
TriplePoint Venture Growth BDC Corp.
(TPVG) is the more profitable company, earning 50. 6% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ICU or TPVG?
In this comparison, TPVG (18.
4% yield) pays a dividend. ICU does not pay a meaningful dividend and should not be held primarily for income.
07Is ICU or TPVG better for a retirement portfolio?
For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.
(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), 18. 4% yield). Both have compounded well over 10 years (TPVG: +93. 3%, ICU: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ICU and TPVG?
These companies operate in different sectors (ICU (Healthcare) and TPVG (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ICU is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock. TPVG pays a dividend while ICU does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.